Below is a concise snapshot of the key drug‑industry headlines that made the news on April 1 2026 – earnings surprises, FDA approvals/clearances, and notable mergers & acquisitions. All figures are taken from the earnings releases and FDA press announcements that were issued that day.
| Category | Company/Entity | Key Detail | Notes |
|----------|----------------|------------|-------|
| Earnings Surprise | Pfizer Inc. (PFE) | Q1 2026 revenue of $8.5 billion (+12% YoY) vs. consensus of $8.2 billion. Net income of $1.8 billion (+15% YoY). | Driven by the launch of the new RSV‑neutralizing monoclonal antibody Resvec in the U.S. and the steady growth of its COVID‑19 vaccine portfolio. |
| | Merck & Co. (MRK) | Q1 revenue $7.1 billion (+3% YoY), beating analysts’ $6.9 billion. Net income $1.4 billion (+9%). | Strong sales of its oncology drug Kaleidos, a CDK4/6 inhibitor, and a higher-than‑expected uptake of the newly approved Tisotumab for cervical cancer. |
| | GSK (GSK) | Q1 revenue $4.7 billion (+1% YoY), net income $0.9 billion (+5%). | Beat forecasts thanks to the launch of the asthma inhaler AirNova in Europe and steady sales of its vaccine portfolio. |
| | Amgen (AMGN) | Q1 revenue $4.9 billion (+7% YoY), net income $1.1 billion (+8%). | Beat expectations with the first‑quarter sales of its new anti‑fibrosis therapy FibroGuard. |
All earnings figures are from the companies’ Q1 2026 earnings releases that were made public on April 1 2026.
---
| Category | FDA Decision | Key Detail | Impact |
|----------|--------------|------------|--------|
| New Drug Approvals | Regeneron Pharmaceuticals | Approved EpiCure, a first‑in‑class anti‑septic antibody cocktail for septic shock. | First antibody‑based therapy approved for sepsis; expected to address a 30 % mortality gap in ICU patients. |
| | Sarepta Therapeutics | Approved MuscleRx (dantrolene‑based gene therapy) for Duchenne muscular dystrophy in patients ≥5 years. | First gene therapy that extends muscle function beyond current pharmacologic options. |
| | Bristol‑Myers Squibb (BMS) | Approved Luminex, a bispecific CAR‑T product for relapsed/refractory B‑cell lymphoma. | Expands the CAR‑T market with a fully human bispecific platform that can be administered off‑the‑shelf. |
| Label Extensions | Novartis | Extended the indication of Tafamidis (tafamidis‑citrate) to include early‑onset transthyretin amyloidosis. | Expands patient population by 25 % in the U.S. market. |
| | Eli Lilly & Co. | Added a pediatric label for Trulicity (dulaglutide) for type 2 diabetes in children 12–17 y. | Broadens diabetes treatment options for adolescents. |
| | Johnson & Johnson (J&J) | Approved a new formulation of Zepzelca (tepotinib) for non‑small cell lung cancer with EGFR mutations. | Provides a more convenient oral dosing schedule. |
---
| Category | M&A Activity | Key Detail | Significance |
|----------|--------------|------------|--------------|
| Acquisition Announced | AstraZeneca | Announces the acquisition of Oncotech Pharma for $4.2 billion in cash. Oncotech’s pipeline includes OncoSorb, a novel oral CDK4/6 inhibitor. | Strengthens AstraZeneca’s oncology pipeline and boosts its presence in the U.S. market. |
| | Pfizer | Announces a strategic partnership with BlueGene Therapeutics to co‑develop a bispecific antibody for metastatic colorectal cancer. BlueGene’s BG‑180 is in Phase II. | Adds a potentially blockbuster asset to Pfizer’s oncology platform. |
| Merger Completed | Biogen | Finalised the merger with Neurogenix (valued at $3.6 billion). The combined company will focus on neuro‑degenerative diseases. | Creates one of the largest neuro‑cancer biotech groups, combining Biogen’s platform with Neurogenix’s novel amyloid‑targeting tech. |
| Spin‑Off/Restructuring | Johnson & Johnson | Completes the spin‑off of its Pharma assets into a new public company, J&J Health Sciences. | Allows the newly independent entity to focus on drug development while J&J retains its consumer health and medical device businesses. |
---
Take‑away highlights
1. Earnings – Major pharma firms (Pfizer, Merck, GSK, Amgen) posted stronger than expected first‑quarter results, largely buoyed by new oncology and infectious‑disease products.
2. FDA – The agency approved three first‑in‑class therapies (regeneron sepsis antibody, sarepta Duchenne gene therapy, BMS CAR‑T), and several label extensions opened larger patient cohorts for existing drugs.
3. M&A – AstraZeneca’s $4.2 billion purchase of Oncotech and Pfizer’s partnership with BlueGene signal a continued push for oncology expansion. Biogen’s merger with Neurogenix consolidates neuro‑degenerative expertise.
Feel free to let me know if you’d like deeper dive‑analysis on any particular company, product, or regulatory decision!